Key facts

Home / Investor relations / Key facts

Financial results (Full-year 2024)

Total Revenue

Changes at constant exchange rates

Core Earnings per Share

Changes at constant exchange rates

Full Year and Q4 2024 results

6 February 2025

Full Year and Q4 2024 results announcement

PDF 1,282KB

Full Year and Q4 2024 results presentation

PDF 3,815KB

Full Year and Q4 2024 results clinical trials appendix

PDF 2,467KB

View all results and presentations

SEC filings

SEC filings are those documents that we are required to file by virtue of our listing on Nasdaq. They contain mainly financial information.

These documents are also available for viewing on the SEC website at www.sec.gov. The Company will send any holder of the Company’s securities, upon request, a hard copy of the Company’s complete audited financial statements free of charge. Requests may be made by writing to:

Company Secretary
AstraZeneca PLC
1 Francis Crick Avenue
Cambridge Biomedical Campus
Cambridge CB2 0AA

View SEC filings

Our pipeline

Our pipeline forms a robust portfolio of investigational therapies in varied stages of clinical development.

196

projects in our pipeline

19

new molecular entities in our late-stage pipeline

1

new molecular entity under review
See our pipeline

  • Investor Relations contacts

    For investor enquiries, please contact our team

    Contact us

  • Shareholder information

    Please find relevant shareholder information and shareholder tools on this page

    Discover more

  • Shareholder FAQs

    Answers to frequently asked shareholder questions

    Find our FAQs

  • Governance

    We apply the principles of good corporate governance in the UK Corporate Governance Code and related guidance

    Go to page